These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 18417122)

  • 1. Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases.
    Wilhelmus MM; van Dam AM; Drukarch B
    Eur J Pharmacol; 2008 May; 585(2-3):464-72. PubMed ID: 18417122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical role of transglutaminase and other stress proteins during neurodegenerative processes.
    Caccamo D; Currò M; Condello S; Ferlazzo N; Ientile R
    Amino Acids; 2010 Feb; 38(2):653-8. PubMed ID: 19960212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue transglutaminase in Alzheimer's disease: involvement in pathogenesis and its potential as a therapeutic target.
    Wilhelmus MM; de Jager M; Bakker EN; Drukarch B
    J Alzheimers Dis; 2014; 42 Suppl 3():S289-303. PubMed ID: 24685636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein misfolding in neurodegenerative diseases.
    Agorogiannis EI; Agorogiannis GI; Papadimitriou A; Hadjigeorgiou GM
    Neuropathol Appl Neurobiol; 2004 Jun; 30(3):215-24. PubMed ID: 15175075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced transglutaminase-catalyzed protein aggregation is observed in the presence of creatine using sedimentation velocity.
    Burguera EF; Love BJ
    Anal Biochem; 2006 Mar; 350(1):113-9. PubMed ID: 16445883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covalent blocking of fibril formation and aggregation of intracellular amyloidgenic proteins by transglutaminase-catalyzed intramolecular cross-linking.
    Konno T; Morii T; Hirata A; Sato S; Oiki S; Ikura K
    Biochemistry; 2005 Feb; 44(6):2072-9. PubMed ID: 15697232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transglutaminase is linked to neurodegenerative diseases.
    Muma NA
    J Neuropathol Exp Neurol; 2007 Apr; 66(4):258-63. PubMed ID: 17413316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transgenic animal models of neurodegenerative diseases and their application to treatment development.
    Rockenstein E; Crews L; Masliah E
    Adv Drug Deliv Rev; 2007 Sep; 59(11):1093-102. PubMed ID: 17869376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ubiquitin proteasome system as a pharmacological target in neurodegeneration.
    Hol EM; Fischer DF; Ovaa H; Scheper W
    Expert Rev Neurother; 2006 Sep; 6(9):1337-47. PubMed ID: 17009921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The transition metals copper and iron in neurodegenerative diseases.
    Rivera-Mancía S; Pérez-Neri I; Ríos C; Tristán-López L; Rivera-Espinosa L; Montes S
    Chem Biol Interact; 2010 Jul; 186(2):184-99. PubMed ID: 20399203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The multifaceted role of transglutaminase in neurodegeneration: review article.
    Karpuj M; Steinman L
    Amino Acids; 2004 Jul; 26(4):373-9. PubMed ID: 15290343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases.
    Martin A; Giuliano A; Collaro D; De Vivo G; Sedia C; Serretiello E; Gentile V
    Amino Acids; 2013 Jan; 44(1):111-8. PubMed ID: 21938398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases.
    Bailey CD; Graham RM; Nanda N; Davies PJ; Johnson GV
    Mol Cell Neurosci; 2004 Mar; 25(3):493-503. PubMed ID: 15033177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical potential of minocycline for neurodegenerative disorders.
    Blum D; Chtarto A; Tenenbaum L; Brotchi J; Levivier M
    Neurobiol Dis; 2004 Dec; 17(3):359-66. PubMed ID: 15571972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications.
    Williams A; Jahreiss L; Sarkar S; Saiki S; Menzies FM; Ravikumar B; Rubinsztein DC
    Curr Top Dev Biol; 2006; 76():89-101. PubMed ID: 17118264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies.
    Chen JF; Chern Y
    Handb Exp Pharmacol; 2011; (200):267-310. PubMed ID: 20859800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoblot analysis reveals that isopeptide antibodies do not specifically recognize the epsilon-(gamma-glutamyl)lysine bonds formed by transglutaminase activity.
    Johnson GV; LeShoure R
    J Neurosci Methods; 2004 Apr; 134(2):151-8. PubMed ID: 15003381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Transglutaminase and neurodegenerative diseases].
    Liu Z; Zeng J; Zeng S; Tang B; Wang J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Aug; 32(4):562-6. PubMed ID: 26252108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanisms.
    Liu T; Bitan G
    ChemMedChem; 2012 Mar; 7(3):359-74. PubMed ID: 22323134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.
    Dunkel P; Chai CL; Sperlágh B; Huleatt PB; Mátyus P
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1267-308. PubMed ID: 22741814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.